Epigenetics Market Expected to Reach $4.1 Billion by 2030—Allied Market Research

The global epigenetics market was valued at $1.0 billion in 2020, and is estimated to reach $4.1 billion by 2030, growing at a CAGR of 14.8% from 2021 to 2030. Epigenetics is an area of developmental biology that involves study of cellular and physiological trait variations initiated by external or ecological aspects. This external stimulus turns genes “on” and “off” and affects ability of cells to read genes. Epigenetics changes phenotype of an organism rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. For instance, DNA methylation and histone modification are epigenetic processes wherein alteration in gene expression is observed without change in the DNA sequence. Increase in use and application of epigenetics to formulate drugs to treat different oncology and non-oncology-related diseases is expected to boost the market growth.

Rise in cancer prevalence; increase in funding & aids for R&D activities; rise in partnership between academic, pharmaceutical, & biotechnology companies for epigenetics studies; and increase in application of epigenetics in non-oncology diseases majorly drives the market growth. In addition, various product launch, collaborations, and other developmental strategies among key players further drive the market. 

For instance, in September 2021, Salarius Pharmaceuticals Inc., a clinical-stage biopharmaceutical firm investigating possible new medications for patients with sarcomas, pediatric malignancies, and other hematologic and solid tumors, announced a research collaboration with Fox Chase Cancer Center's Cancer Epigenetics Institute. The study is expected to aid in identification of additional indications and possible biomarkers for Salariu’s flagship medication candidate, seclidemstat. Thus, such research activities contribute toward growth of the market. However, high cost of instruments and lack of trained professionals are factors that impede the market growth. Conversely, growth opportunities in emerging markets provide lucrative opportunities to the market players.

On the basis of product, it is divided into enzymes, kits, instruments, and reagents. The kits segment generated maximum epigenetics market share revenue in 2020, accounting $394.62 million. The instruments for epigenetics market analysis segment is expected to witness highest CAGR of 16.3% during the forecast period.

On the basis of application, the market is classified into oncology and non-oncology. The oncology segment generated maximum revenue in 2020, accounting for $685.53 million. The epigenetics market size for non-oncology segment is expected to witness highest CAGR of 15.3% during the forecast period.

By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment generated maximum revenue in 2020, accounting $534.53 million. The academic & government research institutes segment is expected to witness highest CAGR of 15.5% during the forecast period.

On the basis of region, the  epigenetics market size of North America generated revenue worth $468.84 million in 2020, and is anticipated to dominate the global epigenetics market in the future. This is attributed to developed healthcare infrastructure, wide availability of advanced epigenetics products, large presence of key players, and presence of trained medical professionals. However, Asia-Pacific is expected to witness highest growth rate during the forecast period, owing to rise in awareness related to epigenetics industry, increase in penetration of key players in emerging countries in Asia-Pacific, and development in infrastructure for research and clinical settings.